Breast cancer is one of the most common cancers in China - and it is on the rise

George ClinicalAmong women in China, rates of breast cancer rose around 3.5% each year between 2000 and 2013. In comparison, breast cancer among American women decreased by about 0.4% a year over the same timeframe. China's rapid urbanisation and development of multiple 'megacities' - a city with 10 million or more inhabitants - reveals higher rates of breast cancer in urban areas, and in more densely-populated areas. In Chinese cities where the population is 1 million or more, the incidence of breast cancer is 60 per 100,000 women.

Dr. Lee Schwartzberg, Executive Director of the West Cancer Center, a leading oncology research and treatment practice, and oncology scientific lead at George Clinical says the increase in breast cancer among women in China is likely due to many factors.

"There are various risk factors associated with breast cancer. These include being less physically active, consuming alcohol or having an unhealthy diet. For women, reproductive factors, like having fewer children, might increase risk."

China's notorious one-child policy was in place from the late 1970s until 2015 (when it was replaced with a two-child policy) and reduced the country's birth rate. The average age of women at the birth of their first child has also risen, as has contraceptive use, and rates of breastfeeding - which has been linked to a reduced risk of breast cancer - have declined.

Twenty years ago, the state of public health in China was similar to most countries in the developing world. Now, thanks to urbanisation and the country's economic growth, China is facing health issues more commonly seen in wealthier countries like the UK or the US. Chronic and non-infectious diseases have been increasing in China, driven by higher incomes, an ageing population, and higher urban density. "These benefits of a growing economy may contribute to greater cancer risk for China's population," says Dr. Schwartzberg. Increased stress levels, associated with larger cities, may affect the immune system or hormones, and encourage the growth of cancer. Similarly, ageing is a critical factor in the incidence of breast cancer: women in China are living longer than ever. Screening for breast cancer in the country faces challenges, with low coverage and variations in different geographic regions.

The general risk factors associated with chronic disease and cancers also likely contribute to the rise in breast cancer rates in China. Rates of physical activity among women in China have decreased, rates of obesity have increased, and alcohol intake - which is associated with increased risk for several cancers including breast cancer - has risen in China.

China's increase in rates of chronic disease is a sign of its increased prosperity over the last twenty years. However, many of the risks associated with breast cancer among women can be reduced or avoided, by raising cancer awareness and improving knowledge on diet, exercise, and breast cancer screening.

For further information about George Clinical, please visit:
https://www.georgeclinical.com/therapeutic-expertise/oncology-cro

George Clinical is a leading independent Asia-Pacific based clinical research organisation (CRO) with global capabilities differentiated by scientific leadership, innovation, and extensive investigator networks. With staff operating in over 15 countries, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration, and post-marketing trials. George Clinical combines scientific and clinical leadership with expert trial delivery capability to create a distinctive world-class service.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...